PMV Investors
PMV Pharma is developing first-in-class p53 regulators for the treatment of cancer. PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Estimated Revenue:
$10M to $50M
Industry:
Asset Management, Business Development, Enterprise Software, Financial Services, Venture Capital
Number Of Exists:
13
Technology:
DeepTech, SpaceTech
Founded Date:
2013
Investor Type:
Government Office, Venture Capital
Headquarters:
Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Employee Number:
51-100
Investment Stage:
Early Stage Venture